Edition:
India

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

0.80USD
8:32pm IST
Change (% chg)

$0.01 (+0.64%)
Prev Close
$0.79
Open
$0.81
Day's High
$0.81
Day's Low
$0.77
Volume
33,724
Avg. Vol
69,403
52-wk High
$3.09
52-wk Low
$0.42

Latest Key Developments (Source: Significant Developments)

Azurrx Biopharma Announces Positive Cff Dsmb Review Of Final Phase 2 Option Trial Data
Thursday, 17 Oct 2019 

Oct 17 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA ANNOUNCES POSITIVE CFF DSMB REVIEW OF FINAL PHASE 2 OPTION TRIAL DATA.AZURRX BIOPHARMA INC - NO SAFETY CONCERNS CITED FOR MS1819-SD.AZURRX BIOPHARMA - POSITIVE REVIEW SUPPORTS PLAN TO PROCEED TO HIGHER 4-GRAM DOSE OF MS1819-SD IN NEXT PHASE 2 TRIAL.AZURRX BIOPHARMA - LOOK FORWARD TO INITIATING NEXT PHASE 2 STUDY OF MS1819-SD AT HIGHER DOSE IN EARLY 2020.AZURRX BIOPHARMA - SAFETY PROFILE OF MS1819 AT 2-GRAM DOSE IN BOTH PHASE 2 STUDIES FOR CYSTIC FIBROSIS REPORTED NO SERIOUS ADVERSE EVENTS.  Full Article

AzurRx Biopharma Announces Positive Results From Phase 2 Trial With MS1819 In Cystic Fibrosis Patients
Wednesday, 25 Sep 2019 

Sept 25 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH MS1819 IN CYSTIC FIBROSIS PATIENTS.AZURRX BIOPHARMA - POSITIVE SAFETY RESULTS FROM PHASE II OPTION CLINICAL TRIAL OF MS1819 FOR TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY IN CF.AZURRX BIOPHARMA - CO IS PLANNING TO MEET WITH FDA BEFORE YEAR-END TO DISCUSS PHASE IIB/III TRIAL DESIGN.  Full Article

Azurrx Biopharma Announces Proposed Public Offering Of Common Stock
Thursday, 18 Jul 2019 

July 17 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AZURRX BIOPHARMA - TO USE NET PROCEEDS FOR RESEARCH AND DEVELOPMENT EXPENSES ASSOCIATED WITH AZURRX'S CONTINUING CLINICAL DEVELOPMENT AND TESTING OF MS1819-SD.AZURRX BIOPHARMA INC - NET PROCEEDS FROM OFFERING PRIMARILY FOR ADVANCING ITS PRECLINICAL PROGRAMS FOR AZX1103.  Full Article

Azurrx Biopharma Inc Files For Mixed Shelf Of Up To $50 Million
Wednesday, 5 Jun 2019 

June 5 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING.  Full Article

Azurrx Biopharma Initiates Phase II Clinical Trial Of MS1819-Sd For Cystic Fibrosis
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA ANNOUNCES INITIATION OF PHASE II OPTION CLINICAL TRIAL OF MS1819-SD IN CYSTIC FIBROSIS PATIENTS.AZURRX BIOPHARMA INC - PLANNED ENROLLMENT IS EXPECTED TO INCLUDE APPROXIMATELY 30 CF PATIENTS, WITH STUDY COMPLETION ANTICIPATED IN 2019.AZURRX BIOPHARMA INC - INITIAL TOP LINE DATA FROM PHASE II OPTION STUDY EXPECTED IN 2019.  Full Article

AzurRx Biopharma To Acquire Payment Rights To Lead Drug Candidate MS1819-SD From Protea Biosciences Group
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA TO ACQUIRE PAYMENT RIGHTS TO LEAD DRUG CANDIDATE MS1819-SD FROM PROTEA BIOSCIENCES GROUP.AZURRX BIOPHARMA INC - WILL PAY A TOTAL OF $1.55 MILLION FOR ASSETS.AZURRX BIOPHARMA INC - WILL ELIMINATE A $2 MILLION MILESTONE PAYMENT THAT WOULD HAVE BEEN DUE TO PROTEA UPON FDA APPROVAL OF MS1819-SD.AZURRX BIOPHARMA - TRANSACTION WAS APPROVED BY JUDGE PATRICK FLATLEY OF U.S. BANKRUPTCY COURT FOR NORTHERN DISTRICT OF WEST VIRGINIA.AZURRX BIOPHARMA - CO WILL NO LONGER BE OBLIGATED TO PAY 2.5% ROYALTY THAT WOULD HAVE BEEN DUE ON 1ST $100 MILLION OF NET SALES OF MS1819-SD.AZURRX BIOPHARMA - DEAL REMOVES REQUIREMENT PROTEA GET 10% OF TOTAL CONSIDERATION FOR MS1819-SD OR CO IF PRODUCT OR PROTEA WERE ACQUIRED BY 3RD PARTY.AZURRX BIOPHARMA - EXPECT TO ANNOUNCE ADDITIONAL KEY MILESTONES BEFORE YEAR-END FOR PHASE 2 STUDY OF MS1819-SD IN CYSTIC FIBROSIS PATIENTS.  Full Article

Azurrx Biopharma Files For Mixed Shelf Of Up To $50 Million - SEC Filing
Wednesday, 4 Jul 2018 

July 3 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA FILES FOR MIXED SHELF OF UP TO $50 MILLION - SEC FILING.  Full Article

Laurence W Lytton Reports 6.15 Pct Passive Stake In Azurrx Biopharma As Of May 1
Saturday, 12 May 2018 

May 11 (Reuters) - AzurRx BioPharma Inc ::LAURENCE W LYTTON REPORTS 6.15 PERCENT PASSIVE STAKE IN AZURRX BIOPHARMA INC AS OF MAY 1 - SEC FILING.  Full Article

AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Azurrx Biopharma Inc ::AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY.AZURRX BIOPHARMA INC - IN PARTNERSHIP WITH MAYOLY SPINDLER, RECEIVED REQUIRED APPROVALS TO ADD A FRENCH SITE TO PHASE IIA STUDY OF MS1819-SD.  Full Article

AzurRx Biopharma files for mixed shelf offering of up to $10 mln
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - AzurRx Biopharma Inc :AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing‍​.  Full Article